StockNews.com Begins Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC)

StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research note issued to investors on Friday. The firm issued a sell rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Price Performance

Shares of CYCC opened at $0.98 on Friday. The company has a market capitalization of $1.43 million, a price-to-earnings ratio of -0.04 and a beta of 0.52. Cyclacel Pharmaceuticals has a fifty-two week low of $0.95 and a fifty-two week high of $11.34. The business’s 50-day moving average is $1.34 and its 200-day moving average is $1.78.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.11. Cyclacel Pharmaceuticals had a negative return on equity of 1,901.11% and a negative net margin of 21,963.75%. During the same quarter in the prior year, the firm posted ($6.60) earnings per share. Equities research analysts expect that Cyclacel Pharmaceuticals will post -2.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cyclacel Pharmaceuticals stock. Armistice Capital LLC acquired a new position in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned approximately 9.18% of Cyclacel Pharmaceuticals at the end of the most recent quarter. Institutional investors own 23.58% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.